Clinical Trials Logo

Prader-Willi Syndrome clinical trials

View clinical trials related to Prader-Willi Syndrome.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05387798 Withdrawn - Clinical trials for Prader-Willi Syndrome

A Phase 3 Extension Study of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi Syndrome

Start date: January 2023
Phase: Phase 3
Study type: Interventional

This is a Phase 3 open-label extension (OLE) study in patients diagnosed with Prader-Willi Syndrome (PWS) who completed the Maintenance Period of the randomized, placebo-controlled Phase 2/3 study SCOUT-015. The primary objective of this study is to assess the long-term safety and tolerability of RAD011.

NCT ID: NCT05198362 Withdrawn - Clinical trials for Prader-Willi Syndrome

Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome

PWS
Start date: December 28, 2021
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of Tesomet (tesofensine + metoprolol) in subjects with PWS.

NCT ID: NCT04396470 Withdrawn - Clinical trials for Prader-Willi Syndrome

tVNS in Children With Prader-Willi Syndrome

Start date: July 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the current project is to test the impact of transcutaneous vagus nerve stimulation (tVNS) on social ability in children with Prader-Willi Syndrome (PWS). Social ability and blood neuropeptides associated with social functioning will be measured before and after engagement in 12 weeks of tVNS therapy.

NCT ID: NCT04086810 Withdrawn - Clinical trials for Prader-Willi Syndrome

An Open-Label Study of DCCR Tablet in Patients With PWS

Start date: October 2019
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to monitor the long-term safety of DCCR in PWS patients.

NCT ID: NCT04066088 Withdrawn - Clinical trials for Prader-Willi Syndrome

Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome

Start date: December 1, 2019
Phase: Phase 4
Study type: Interventional

This is a placebo-controlled clinical trial to assess the utility of Guanfacine Extended Release (GXR) in the management of patients with Prader Willi Syndrome (PWS) who have significant aggression or self-injury. The purpose of this trial is to establish the safety of GXR with a specific focus on metabolic effects.

NCT ID: NCT03831425 Withdrawn - Clinical trials for Prader-Willi Syndrome

Mitochondrial Complex I Dysfunction in PWS

Start date: June 1, 2023
Phase: Phase 2
Study type: Interventional

Prader-Willi Syndrome (PWS) is characterized by profound infantile hypotonia, growth delay, cognitive impairment, muscle weakness and exercise intolerance. Studies have suggested that a defect in energy metabolism, yet to be clarified, may be involved in its pathogenesis. Many PWS patients have received Coenzyme Q10, but the rationale for this and objective impact on cellular metabolism has not been clarified.